Notable Labs Corp (NTBL): Price to Sales

Symbol and logo of brand Notable Labs Inc. (NTBL)

Notable Labs, Ltd. (NTBL) is developing the advanced PPMP IT system to analyze therapy efficacy on live cells. The method is based on the functional diagnostics of thousands of drugs to determine the ideal treatment. The median P/S helps assess the business value relative to revenue, where 7.70 captures the magnitude of this parameter. The process is completed by a streamlined express bio-sample transport network, ensuring the accuracy of laboratory research.

NTBL - Notable Labs, Ltd. P/S Multiple over the range 02/21/2024 - 11/02/2024

Metric breakdowns and analytics for Notable Labs Inc. (NTBL)

- stock price and consensus target price:
Share Price notablelabs.com|NTBL - Price Target Chart
- stock exchange capitalization data:
Market Value Notable Labs Inc.|NTBL - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Price of a Share Notable Labs|NTBL - Book Capitalization|Market Capitalization to Book Value Ratio notablelabs.com|NTBL - Company Total Assets
- business debt structure and liquidity details:
Debt to Equity Notable Labs, Ltd.|NTBL - Long-Term Debt to Equity|Short-Term Debt to Equity Notable Labs Corp|NTBL - Company Aggregate Debts|Debts to Book Value Notable Labs Inc.|NTBL - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Notable Labs|Quick Liquidity notablelabs.com
- earnings and market ratios statistics:
NTBL - Net Profit|Projected Future Earnings Notable Labs, Ltd.|NTBL - P/E Multiple|Future Price to Earnings Notable Labs Ltd|NTBL - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Notable Labs Inc.|NTBL - Operating profit before deduction of amortization|Earnings per share for the trailing year Notable Labs|NTBL - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months notablelabs.com|NTBL - Net earnings per share growth this year|Projected earnings per share increase next year Notable Labs, Ltd.
- issuer revenue and sales details:
NTBL - Revenue and Sales Volume|Company Revenue Forecast notablelabs.com|NTBL - Market Cap to Revenue|Market Cap to Expected Sales Ratio Notable Labs Inc.
General company analysis:NTBL - notablelabs.com
Product sample of Notable Labs Corp

Notable Labs, Ltd. (NTBL) independence from macroeconomic cycles and the steady demand for medtech innovations make the current P/S ratio a key indicator of market confidence in the company's capital-intensive business development. This metric reflects the company's valuation relative to its revenue, allowing investors to assess the premium paid for every dollar of sales and determine the extent to which quotes are overvalued relative to actual operating income.

Who Notable Labs, Ltd. competes with

beigene.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Halozyme HALO|Revolution Medicines Inc (RVMD) - Price to Sales|AAPG: Market Cap to Revenue|CG Oncology Therapeutics - Market Cap to Sales Volume|URGN: P/S Multiple|bicara.com (BCAX) - P/S Multiple|PSNL (Personalis) - P/S Multiple|Price-to-Revenue Ratio ERAS|Price-to-Revenue Ratio Delcath (DCTH)|Price-to-Revenue Ratio YMAB (Y-mAbs Corp)|P/S Multiple AURA (Aura Biosciences, Inc.)|Candel Therapeutics Inc. (CADL) - Price to Sales|ARAY: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SLS (SELLAS Life Sciences)|Actuate Therapeutics, Inc (ACTU) - Price-to-Revenue Ratio|CTOR (Citius Oncology Inc) - Price-to-Revenue Ratio|HURA (TuHURA Biosciences Inc.) - P/S Multiple|P/S Multiple protaratx.com|P/S Multiple FATE|Price-to-Revenue Ratio WHWK (aadibio.com)|Price-to-Revenue Ratio TScan Therapeutics, Inc. TCRX|Price-to-Revenue Coefficient Champions Oncology Inc (CSBR)|XBIT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CVM (CEL-SCI Corporation)|OS Therapies (OSTX) - Price-to-Revenue Ratio|RADX (radiopharmtheranostics.com) - Price-to-Revenue Ratio|Market Cap to Revenue ARTV|ANL (Adlai Nortye Limited) - Market Cap to Sales Volume|P/S Multiple VERU|tempesttx.com - Market Cap to Revenue Ratio|Xilio Therapeutics - Market Cap to Revenue|Price-to-Revenue Coefficient Renovaro Biosciences (RENB)|MURA - Price-to-Revenue Ratio|KAPA (Kairos Pharma Ltd) - Market Cap to Revenue Ratio|OKUR (onkuretherapeutics.com) - Market Cap to Revenue|GDTC: Market Cap to Sales Volume|CRIS (Curis Inc.) - P/S Multiple|Price-to-Revenue Ratio APLM|Price-to-Revenue Ratio Tharimmune Corp (THAR)|Price-to-Revenue Ratio ADVB (advanbiomed.com)|P/S Multiple GNPX (Genprex, Inc.)|CLDI - Market Cap to Revenue|Sunshine Biopharma, Inc. - P/S Multiple|XBIO - P/S Multiple|Salarius (SLRX) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio PPBT|AONC (American Oncology Network Inc) - P/S Multiple|Market Cap to Revenue beigene.com (BGNE)|P/S Multiple CKPT|ELEV - Price to Sales|Price-to-Revenue Ratio iCAD ICAD|Market Capitalization-to-Revenue Ratio IKNA|VIRX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio MOR (morphosys.com)|NAYA: P/S Multiple|Market Cap to Revenue Ascentage Pharma Group International